Terremoto Biosciences
Clinical-stage biotechnology company developing targeted small-molecule therapies using lysine‑targeted covalent chemistry. Advances discovery programs through IND-enabling studies and Phase 1 clinical development, with active regulatory engagement. Headquartered in South San Francisco with additional presence in San Diego. Leadership and functional teams include discovery chemistry, structural biology, preclinical pharmacology, clinical development, regulatory operations, technical operations/CMC, quality, and informatics.
Industries
Nr. of Employees
medium (51-250)
Terremoto Biosciences
South San Francisco, California, United States
Patents
Products
TER-2013
Investigational, orally bioavailable small-molecule inhibitor designed to selectively target AKT1. Evaluated in a Phase 1 clinical trial (NCT-07109726) for solid tumors harboring AKT/PI3K/PTEN pathway alterations; granted FDA Fast Track designation for a specific breast cancer indication.
TER-4480
Small-molecule program targeting hereditary hemorrhagic telangiectasia (HHT); program expected to enter clinical evaluation following preclinical development.
TER-2013
Investigational, orally bioavailable small-molecule inhibitor designed to selectively target AKT1. Evaluated in a Phase 1 clinical trial (NCT-07109726) for solid tumors harboring AKT/PI3K/PTEN pathway alterations; granted FDA Fast Track designation for a specific breast cancer indication.
TER-4480
Small-molecule program targeting hereditary hemorrhagic telangiectasia (HHT); program expected to enter clinical evaluation following preclinical development.
Expertise Areas
- Covalent small-molecule discovery (lysine-targeted)
- Structure-based drug design
- Medicinal chemistry for isoform-selective inhibitors
- Computational drug discovery and cheminformatics
Key Technologies
- Lysine-targeted covalent small-molecule chemistry
- Structure-based design
- Cryo-electron microscopy
- X-ray crystallography
News & Updates
Series A financing to advance a lysine-targeted covalency platform and develop small-molecule therapies; financing co-led by OrbiMed and Third Rock Ventures.
Series B financing to advance the company's platform and multiple in-house discovery and development programs.
Series C financing to advance selective AKT1 inhibitors in oncology and hereditary hemorrhagic telangiectasia.
FDA granted Fast Track designation for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN alterations.
Charles Baum named CEO; transition of prior leadership roles noted.
James Christensen appointed President and Head of Research & Development.
Series A financing to advance a lysine-targeted covalency platform and develop small-molecule therapies; financing co-led by OrbiMed and Third Rock Ventures.
Series B financing to advance the company's platform and multiple in-house discovery and development programs.
Series C financing to advance selective AKT1 inhibitors in oncology and hereditary hemorrhagic telangiectasia.
FDA granted Fast Track designation for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN alterations.
Charles Baum named CEO; transition of prior leadership roles noted.
James Christensen appointed President and Head of Research & Development.